caa a22 4500 469116498 CHVBK 20180323133126.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF00172945 doi (NATIONALLICENCE)springer-10.1007/BF00172945 Systemic treatment with murine recombinant interleukin-1β inhibits the growth and progression of malignant glioma in the rat [Elektronische Daten] [Charles Rice, Randall Merchant] We investigated the effects of daily subcutaneous (SC) injections of 100, 200, or 400 μg/kg murine recombinant interleukin-1β (rIL-1β) or its excipient on normal Fischer 344 rats and ones harboring a malignant RT-2 glioma. The tumor model has a predictable course with animals dying on days 14-17 following an intracerebral inoculation of 104 RT-2 glioma cells. Treatments with (rIL-1β) or excipient began on day seven post-tumor inoculation and continued for 7 days. We observed no significant effect on core body temperatures although there was a significant (p < 0.05) decrease in body weight in all (rIL-1β) treated animals. When tumor-bearing animals became moribund, they received an intraperitoneal injection of bromodeoxyuridine (BUdr) and were sacrificed two hours later. Blood samples were obtained prior to their sacrifice by transcardiac perfusion with a buffered aldehyde solution. Recombinant IL-4ß affected blood differentials; causing neutrophilia, lymphopenia, and slight thrombocythemia. The BUdr labeling index of glioma cells did not significantly differ between treatment groups, although tumors differed histologically at the time of necropsy. Tumors of rIL-1β treated animals had more extensive necrosis and a greater degree of leukocyte infiltration. Survival studies were conducted in which rats were given continuous daily SC injections of (rIL-1β) until day of death. Overall survival between the two groups differed significantly in studies using 100 μg/kg/d (p < 0.05); (rIL-1ß) treated rats had a mean survival time of 22 (± 3.0) days while excipient controls had a mean survival time of 17 (± 0.5) days. Similarly, at a dose of 200 μg rIL-1(3/kg/d), mean survival was significantly (p < 0.05) increased as compared to excipient controls (18.75 ± 1.5 vs. 15.25 ± 1.7 days, respectively). Daily injections of 400 μg/kg did not significantly increase the survival of glioma bearing animals, possibly as a consequence of fIL-1ß toxicity at this dose. Kluwer Academic Publishers, 1992 IL-1β nationallicence glioblastoma nationallicence angiogenesis nationallicence leukocytes nationallicence survival nationallicence toxicity nationallicence Rice Charles Department of Anatomy, Medical College of Virginia, Richmond, Virginia, USA aut Merchant Randall Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 13/1(1992-05-01), 43-55 0167-594X 13:1<43 1992 13 11060 https://doi.org/10.1007/BF00172945 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172945 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rice Charles Department of Anatomy, Medical College of Virginia, Richmond, Virginia, USA aut NATIONALLICENCE 700 1- Merchant Randall Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 13/1(1992-05-01), 43-55 0167-594X 13:1<43 1992 13 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer